Fig. 1
From: AUY922 induces retinal toxicity through attenuating TRPM1
Treatment with AUY922 induced retinal dysfunction. a Full field electroretinogram (ffERG) of a patient with refractory gastrointestinal stromal tumor who received 70 mg/m2 weekly AUY922 treatment for 2 months before withdrawing treatment for 3 months. OD: right eye, OS: left eye. b Representative images of apoptotic cells (top), cleaved caspase-3 (middle) and GFAP (bottom) expression, as determined by TUNEL assay and IHC analysis, in mouse eye samples from nude mice bearing A375 xenograft tumors, after treatment with mock, 25 mg/kg AUY922 three times weekly (3qw), or five times weekly (5qw) for 2 w. IS: inner segment; OS: outer segment; ONL: outer nuclear layer; OPL: outer plexiform layer; INL: inner nuclear layer; GCL: ganglion cell layer. Scale bar: 25 μm. The arrow indicates the layer vulnerable to AUY922. The percentage of TUNEL-positive and cleaved caspase-3-positive cells and the GFAP IHC score are presented on the right. Data are presented as the mean ± s.e.m. The P values were determined by two-tailed Student’s t-test, *** P < 0.001. n = 4